{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:50:59Z","timestamp":1790628659769,"version":"4.1.0"},"reference-count":45,"publisher":"FapUNIFESP (SciELO)","issue":"4","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["An. Acad. Bras. Ci\u00eanc."],"DOI":"10.1590\/0001-3765202120200632","type":"journal-article","created":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T13:35:00Z","timestamp":1632749700000},"source":"Crossref","is-referenced-by-count":3,"title":["Evaluation of the genetic toxicity of sofosbuvir and simeprevir with and without ribavirin in a human-derived liver cell line"],"prefix":"10.1590","volume":"93","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7194-4653","authenticated-orcid":false,"given":"CARINA S.","family":"LIBRELOTTO","sequence":"first","affiliation":[{"name":"Universidade Luterana do Brasil (ULBRA),  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3297-1058","authenticated-orcid":false,"given":"ANA PAULA DE","family":"SOUZA","sequence":"additional","affiliation":[{"name":"Universidade Luterana do Brasil (ULBRA),  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5001-246X","authenticated-orcid":false,"given":"M\u00c1RIO R.","family":"\u00c1LVARES-DA-SILVA","sequence":"additional","affiliation":[{"name":"Universidade Federal do Rio Grande do Sul (UFRGS),  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1122-8468","authenticated-orcid":false,"given":"DANIEL","family":"SIMON","sequence":"additional","affiliation":[{"name":"Universidade Luterana do Brasil (ULBRA),  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4491-5870","authenticated-orcid":false,"given":"RAFAEL R.","family":"DIHL","sequence":"additional","affiliation":[{"name":"Universidade Luterana do Brasil (ULBRA),  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"530","published-online":{"date-parts":[[2021]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"3602","DOI":"10.1007\/s10620-016-4340-x","article-title":"Sofosbuvir-containing regimens for chronic hepatitis C are successful in the safety-net population: a real-world experience","volume":"61","author":"BECK KR","year":"2016","journal-title":"Dig Dis Sci"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.jhep.2017.01.028","article-title":"Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort","volume":"66","author":"CALLEJA JL","year":"2017","journal-title":"J Hepatol"},{"issue":"4","key":"ref3","doi-asserted-by":"crossref","DOI":"10.1152\/ajpgi.2000.278.4.G522","article-title":"MRP2, a human conjugate export pump, is present and transports fluo 3 into apical vacuoles of Hep G2 cells","volume":"278","author":"CANTZ T","year":"2000","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/em.20282","article-title":"Relative mutagenic potencies of several nucleoside analogs alone or in drug pairs at the HPRT and TK loci of human TK6 lymphoblastoid cells","volume":"48","author":"CARTER MM","year":"2007","journal-title":"Environ Mol Mutagen"},{"issue":"1","key":"ref5","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ejps.2003.07.003","article-title":"The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability","volume":"21","author":"CHAN LM","year":"2004","journal-title":"Eur J Pharm Sci"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.cgh.2017.02.020","article-title":"Real-world effectiveness and safety of oral combination antiviral therapy for hepatitis C virus genotype 4 infection","volume":"15","author":"CRESPO J","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7","key":"ref7","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1042\/BC20070127","article-title":"Which in vitro models could be best used to study hepatocyte polarity","volume":"100","author":"DECAENS C","year":"2008","journal-title":"Biol Cell"},{"issue":"5","key":"ref8","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s40262-014-0142-5","article-title":"Viral hepatitis C therapy: pharmacokinetic and pharmacodynamic considerations","volume":"53","author":"DE KANTER CT","year":"2014","journal-title":"Clin Pharmacokinet"},{"key":"ref9","first-page":"468","article-title":"Mechanism of cytotoxicity of ribavirin in the rat bone marrow and testis","volume":"46","author":"D\u2019SOUZA UJ","year":"2002","journal-title":"Indian J Physiol Pharmacol"},{"key":"ref10","series-title":"Assessment report. International non-proprietary name: simeprevir; Procedure No. EMEA\/H\/C\/002777\/0000; 2014","year":"2014"},{"key":"ref11","series-title":"Assessment report. International non-proprietary name: sofosbuvir\/velpatasvir. Procedure No. EMEA\/H\/C\/004210\/0000","year":"2016"},{"key":"ref12","series-title":"Center for Drug Evaluation and Research. Application number: 204671Orig1s000. Pharmacology Review(s)","author":"FDA M","year":"2013"},{"key":"ref13","series-title":"Center for Drug Evaluation and Research; Application number: 205123Orig1s000; Pharmacology Review(s); 2013","year":"2013"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0027-5107(00)00065-8","article-title":"The in vitro micronucleus technique","volume":"455","author":"FENECH M","year":"2000","journal-title":"Mutat Res"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.mrfmmm.2006.05.028","article-title":"Cytokinesis-block micronucleus assay evolves into a \u201ccytome\u201d assay of chromosomal instability mitotic dysfunction and cell death","volume":"600","author":"FENECH M","year":"2006","journal-title":"Mutat Res"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/nprot.2007.77","article-title":"Cytokinesis-block micronucleus cytome assay","volume":"2","author":"FENECH M","year":"2007","journal-title":"Nat Protoc"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0165-1161(85)90015-9","article-title":"Measurement of micronuclei in lymphocytes","volume":"147","author":"FENECH M","year":"1985","journal-title":"Mutat Res"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.advms.2017.04.004","article-title":"Effectiveness and safety of ledipasvir\/sofosbuvir\u00b1ribavirin in the treatment of HCV infection: The real-world HARVEST study","volume":"62","author":"FLISIAK R","year":"2017","journal-title":"Adv Med Sci"},{"issue":"Suppl 1","key":"ref19","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/liv.13293","article-title":"Hepatitis C: efficacy and safety in real life","volume":"37","author":"FLISIAK R","year":"2017","journal-title":"Liver Int 37"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1515\/jtim-2017-0007","article-title":"Direct Acting Anti-hepatitis C Virus Drugs: Clinical Pharmacology and Future Direction","volume":"5","author":"GEDDAWY A","year":"2017","journal-title":"J Transl Int Med"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.3748\/wjg.v22.i4.1421","article-title":"New approaches in the treatment of hepatitis C","volume":"22","author":"GONZ\u00c1LEZ-GRANDE R","year":"2016","journal-title":"World J Gastroenterol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.fct.2012.12.005","article-title":"Comparative analysis of genetic toxicity of antiretroviral combinations in somatic cells of Drosophila melanogaster","volume":"53","author":"GUIMAR\u00c3ES NN","year":"2013","journal-title":"Food Chem Toxicol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection","volume":"364","author":"JACOBSON IM","year":"2011","journal-title":"N Engl J Med"},{"key":"ref24","first-page":"283","article-title":"Influence of ribavirin on the micronucleus formation and in vitro proliferation of human lymphocytes","volume":"47","author":"JOKSI\u0106 G","year":"2000","journal-title":"Neoplasma"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1620\/tjem.209.347","article-title":"Vitamin B12 reduces ribavirin-induced genotoxicity in phytohemaglutinin-stimulated human lymphocytes","volume":"209","author":"JOKSI\u0106 I","year":"2006","journal-title":"Tohoku J Exp Med"},{"issue":"7","key":"ref26","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s40262-015-0261-7","article-title":"Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of the Hepatitis C Virus NS5B Polymerase Inhibitor Sofosbuvir","volume":"54","author":"KIRBY BJ","year":"2015","journal-title":"Clin Pharmacokinet"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0378-4274(02)00498-8","article-title":"Indirect mechanisms of genotoxicity","volume":"141","author":"KIRSCH-VOLDERS M","year":"2003","journal-title":"Toxicol Lett"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1080\/01480545.2017.1405970","article-title":"Chromosomal instability and cytotoxicity induced by ribavirin: comparative analysis in cell lines with different drug-metabolizing profiles","volume":"42","author":"LIBRELOTTO CS","year":"2019","journal-title":"Drug Chem Toxicol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ijantimicag.2014.04.018","article-title":"Efficacy and safety of sofosbuvir-based therapy for the treatment of chronic hepatitis C in treatment-na\u00efve and treatment-experienced patients","volume":"44","author":"LIU X","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"ref30","first-page":"237","article-title":"Antagonism and antagonist","volume":"9","author":"LOEWE S","year":"1957","journal-title":"Pharmacol Rev"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.biochi.2006.07.004","article-title":"Chromosomal changes: induction detection methods and applicability in human biomonitoring","volume":"88","author":"MATEUCA R","year":"2006","journal-title":"Biochimie"},{"key":"ref32","series-title":"Guidelines for the Testing of Chemicals. In Vitro Mammalian Cell Micronucleus Test (487)","year":"2016"},{"issue":"2","key":"ref33","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s40262-015-0314-y","article-title":"Drug-Drug Interactions with the NS3\/4A Protease Inhibitor Simeprevir","volume":"55","author":"OUWERKERK-MAHADEVAN S","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/COH.0000000000000183","article-title":"Epidemiology of hepatitis C virus in HIV-infected patients","volume":"10","author":"PETERS L","year":"2015","journal-title":"Curr Opin HIV AIDS"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection","volume":"364","author":"POORDAD F","year":"2011","journal-title":"N Engl J Med"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1016\/S1567-5769(01)00132-1","article-title":"Interactions of aspirin and salicylic acid with prednisolone for inhibition of lymphocyte proliferation","volume":"1","author":"RAMAKRISHNAN R","year":"2001","journal-title":"Int Immunopharmacol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/0011-393X(95)85025-2","article-title":"The nonclinical toxicologic profile of stavudine","volume":"56","author":"SCHILLING BE","year":"1995","journal-title":"Curr Ther Res"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0165-1161(75)90058-8","article-title":"The micronucleus test","volume":"31","author":"SCHMID W","year":"1975","journal-title":"Mutat Res"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"11033","DOI":"10.3748\/wjg.v20.i32.11033","article-title":"Chronic hepatitis C and liver fibrosis","volume":"20","author":"SEBASTIANI G","year":"2014","journal-title":"World J Gastroenterol"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1080\/17425255.2017.1351942","article-title":"Drug interactions in HIV-infected patients treated for hepatitis C","volume":"13","author":"SORIANO V","year":"2017","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/em.20264","article-title":"Mutagenicity of zidovudine lamivudine and abacavir following In vitro exposure of human lymphoblastoid cells or in utero exposure of CD-1 mice to single agents or drug combinations","volume":"48","author":"TORRES SM","year":"2007","journal-title":"Environ Mol Mutagen"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/mutage\/geh033","article-title":"Frequency of Tk and Hprt lymphocyte mutants and bone marrow micronuclei in mice treated neonatally with zidovudine and didanosine","volume":"19","author":"VON TUNGELN LS","year":"2004","journal-title":"Mutagenesis"},{"key":"ref43","series-title":"Global hepatitis report","year":"2017"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0140-6736(17)31762-2","article-title":"What is the impact of treatment for hepatitis C virus infection","volume":"390","author":"WIKTOR SZ","year":"2017","journal-title":"Lancet"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2147\/TCRM.S134818","article-title":"Efficacy and safety outcomes of sofosbuvir-based treatment regimens for hepatitis C virus-infected patients with or without cirrhosis from phase III clinical trials","volume":"13","author":"YANG YM","year":"2017","journal-title":"Ther Clin Risk Manag"}],"container-title":["Anais da Academia Brasileira de Ci\u00eancias"],"original-title":[],"deposited":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T13:35:42Z","timestamp":1632749742000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0001-37652021000700601&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":45,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021]]}},"alternative-id":["S0001-37652021000700601"],"URL":"https:\/\/doi.org\/10.1590\/0001-3765202120200632","relation":{},"ISSN":["1678-2690","0001-3765"],"issn-type":[{"value":"1678-2690","type":"electronic"},{"value":"0001-3765","type":"print"}],"subject":[],"published":{"date-parts":[[2021]]},"article-number":"e20200632"}}